Unlocking The Power Of Literature-Based Submissions (LBS): A Strategic Path To Regulatory Approval

In today’s competitive life sciences landscape, companies are under constant pressure to accelerate development timelines, reduce costs, and maintain scientific rigor. Literature-Based Submissions (LBS) have emerged as a powerful regulatory strategy, enabling organizations to leverage existing scientific evidence to support drug approvals, often reducing or eliminating the need for new clinical or non-clinical studies.

When executed effectively, LBS can significantly shorten time-to-market while meeting global regulatory expectations.

What is a Literature-Based Submission (LBS)?

A Literature-Based Submission (LBS) is a regulatory approach that uses published scientific literature as primary evidence to demonstrate the safety, efficacy, and clinical relevance of a drug, reducing the need for new studies.

A Literature-Based Submission is a regulatory filing strategy that compiles and analyzes peer-reviewed scientific publications to support:

• Safety and efficacy 
• Pharmacokinetics/pharmacodynamics (PK/PD) 
• Clinical outcomes and real-world effectiveness 

Applicability

LBS is most suitable when:

• The active substance has well-established use (typically ≥10 years) 
• Extensive clinical experience exists across multiple regions 
• Sufficient published evidence supports benefit-risk 

CTD Module Utilization

• Module 3 (Quality): Requires original data 
• Module 4 (Non-clinical): Can rely on literature 
• Module 5 (Clinical): Primarily literature-driven 

Why LBS Matters in Modern Regulatory Strategy

• Reduces dependency on new clinical trials 
• Accelerates regulatory timelines 
• Optimizes development costs 
• Leverages global scientific knowledge 
• Supports lifecycle management strategies 

When Is LBS the Right Strategy?

Common Use Cases

• Generics with well-established active substances 
• Line extensions (new dosage forms, strengths) 
• New therapeutic indications 
• Drug repurposing strategies 
• Orphan drug applications using observational data 
• Submissions in reliance or literature-accepting markets 

LBS Suitability Framework

Key Components of a Successful LBS

1. Early Engagement with Regulatory Authorities

Engage early with agencies such as:

• FDA 
• EMA 
• TGA 
• MHRA 

Benefits:

• Clarifies acceptability of literature-based evidence 
• Aligns expectations on data requirements 
• Reduces risk of rejection 

2. Comprehensive Literature Search Strategy

A robust search strategy is critical for credibility.

Key Databases

• PubMed 
• EMBASE 
• Cochrane Library 
• Web of Science 

Structured Approach

Use frameworks like PICO (Patient, Intervention, Comparison, Outcome) to ensure systematic and relevant data retrieval.

3. Transparent Methodology & Documentation

• Define inclusion/exclusion criteria 
• Maintain screening logs 
• Document search protocols 

Quality Appraisal Tools

• GRADE (Grading of Recommendations Assessment) 
• CASP (Critical Appraisal Skills Programme) 

Transparency builds regulatory trust and audit readiness.

4. Developing a Cohesive Scientific Narrative

An effective LBS is not just a collection of studies, it is a well-structured scientific argument.

Key Elements

• Data synthesis across studies 
• Consistency and reproducibility 
• Clinical relevance and applicability 
• Clear benefit-risk profile 

5. Addressing Biases and Data Gaps

Regulators expect acknowledgment of limitations.

Best Practices:

• Highlight inconsistencies 
• Discuss publication bias 
• Provide justification for missing data 

6. Standardized Formatting & eCTD Readiness

• Use consistent templates and terminology 
• Ensure alignment with ICH CTD guidelines 
• Prepare fully eCTD-compliant modules 

BS Best Practices

Regulatory Expectations & Considerations

Key Requirements

• Scientific validity of literature 
• Relevance to target population and indication 
• Consistency across studies 
• Justified extrapolation of data 

Common Challenges

• Heterogeneity of study designs 
• Limited head-to-head comparisons 
• Variability in endpoints and outcomes 

Advantages of Literature-Based Submissions

1. Faster Time-to-Market

Avoid lengthy clinical trials and accelerate approvals.

2. Cost Efficiency

Reduce R&D and clinical trial expenses.

3. Broader Evidence Base

Leverage diverse global datasets and real-world evidence.

4. Regulatory Flexibility

Applicable across multiple regulatory pathways and regions.

LBS Benefits Overview

Limitations and Risk Mitigation

Key Risks

• Data quality variability 
• Publication bias 
• Regulatory skepticism 
• Insufficient evidence for novel claims 

Mitigation Strategies

• Use high-quality, peer-reviewed sources 
• Apply rigorous critical appraisal 
• Supplement with bridging data if needed 
• Engage regulators early 

Emerging Trends in LBS

• Integration of Real-World Evidence (RWE) 
• AI-powered literature screening and data extraction 
• Increased acceptance in global reliance pathways 
• Use in precision medicine and rare diseases 
• Digital transformation of regulatory submissions 

Regulatory & Scientific Expertise

Maven Scientific Laboratories specializes in literature-based regulatory strategies and submissions.

Proven Global Experience

Our expertise includes:

• LBS across FDA, EMA, and global markets 
• CTD and eCTD submissions 
• Regulatory medical writing excellence 

Scientific Authority

Our team includes:

• Medical writers 
• Clinical experts 
• Regulatory strategists 
• Data analysts 

Trust Through Quality & Compliance

We assure you:

• Transparent methodologies 
• High-quality documentation 
• Regulatory-ready submissions 

Accelerate Approval with LBS

Partner with Maven Scientific Laboratories

Looking to leverage literature-based submissions?

We will help you.

• Design robust literature strategies 
• Conduct systematic reviews 
• Develop compelling regulatory narratives 
• Prepare eCTD-ready submissions 

Our Services

• Literature search and systematic review 
• Clinical overview and summary writing 
• Benefit-risk assessment 
• CTD module preparation 
• Regulatory submission support 

Why Choose Maven

• Deep regulatory and scientific expertise 
• End-to-end LBS support 
• High-quality medical writing 
• Faster, compliant approvals 

Conclusion

Literature-Based Submissions are not just an alternative pathway they are a strategic advantage in modern regulatory science.

By effectively leveraging existing scientific evidence, companies can:

• Accelerate approvals 
• Reduce development costs 
• Strengthen regulatory confidence 

With the right strategy and expert support, LBS can unlock faster, smarter, and more efficient pathways to market success.

FAQs 

1. What is a literature-based submission (LBS)?
A regulatory submission using published scientific data instead of new studies.

2. When can LBS be used?
For well-established drugs, generics, new indications, and repurposed products.

3. Which CTD modules use literature?
Primarily Modules 4 and 5, while Module 3 requires original data.

4. What are the benefits of LBS?
Faster approvals, lower costs, and broader evidence utilization.

5. What are the risks of LBS?
Data variability, bias, and regulatory acceptance challenges.

6. Do regulators accept LBS globally?
Yes, in many regions with proper justification and quality data.

7. How can Maven help?
By providing end-to-end LBS strategy, medical writing, and regulatory support.